| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Satoshi Kasahara, Miwako Takahashi, Takashi Suto, Taito Morita, Hideaki Obata, Shin-Ichi Niw. Innovative therapeutic strategies using ADHD medications tailored to the behavioral characteristics of patients with chronic pain. Frontiers in pharmacology. vol 16. 2025-03-13. PMID:40078279. |
additionally, increased norepinephrine synthesis and reduced transmission efficiency amplify nociceptive information from the periphery and facilitate central sensitization in adhd. |
2025-03-13 |
2025-03-15 |
Not clear |
| Satoshi Kasahara, Miwako Takahashi, Takashi Suto, Taito Morita, Hideaki Obata, Shin-Ichi Niw. Innovative therapeutic strategies using ADHD medications tailored to the behavioral characteristics of patients with chronic pain. Frontiers in pharmacology. vol 16. 2025-03-13. PMID:40078279. |
beyond typical adhd medications like central stimulants, norepinephrine reuptake inhibitors, and alpha-2 receptor agonists, various antidepressants, mood stabilizers, antipsychotics, parkinson's disease medications, and antidementia medications have proven effective in alleviating adhd symptoms. |
2025-03-13 |
2025-03-15 |
Not clear |
| Nurullah Bolat, Merve Meliha Hız-Çelikliyurt, Erhan Akıncı, Gülsüm Akkuş, Melih Günay, Şükrü Alperen Korkma. Drug and chemical toxicology. 2025-01-28. PMID:39871457. |
although atomoxetine, a selective norepinephrine reuptake inhibitor, is widely used in the treatment of attention-deficit/hyperactivity disorder (adhd), there is limited data on its cytogenetic effects. |
2025-01-28 |
2025-01-30 |
Not clear |
| Jean Taj Vilus, Caitlin Engelhar. Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatric annals. vol 54. issue 1. 2025-01-06. PMID:39760346. |
the recommended nonstimulant adhd medications include alpha agonists (eg, guanfacine extended-release [er], clonidine er) and norepinephrine reuptake inhibitors (eg, atomoxetine, viloxazine). |
2025-01-06 |
2025-01-08 |
Not clear |
| Jincao Zhi, Shiwen Zhang, Meiling Huang, Huan Qin, He Xu, Qing Chang, Yan Wan. Transcutaneous auricular vagus nerve stimulation as a potential therapy for attention deficit hyperactivity disorder: modulation of the noradrenergic pathway in the prefrontal lobe. Frontiers in neuroscience. vol 18. 2024-12-19. PMID:39697776. |
one of the pathogenic mechanisms of adhd involves abnormalities in the norepinephrine (ne) pathway within the prefrontal cortex (pfc). |
2024-12-19 |
2024-12-21 |
Not clear |
| Hirotsugu Kaneshima, Naoya Miura, Asuka Tsuchiya, Seiji Morita, Yoshihide Nakagaw. Atomoxetine-Induced Pheochromocytoma and Paraganglioma Crisis Managed With Veno-Arterial Extracorporeal Membrane Oxygenation. Cureus. vol 16. issue 11. 2024-12-16. PMID:39677247. |
pheochromocytoma and paragangliomas (ppgls) crises can be triggered by various factors, including norepinephrine reuptake inhibitors used to treat attention deficit hyperactivity disorder (adhd), which worsen symptoms in patients with ppgls. |
2024-12-16 |
2024-12-21 |
Not clear |
| Majlen A Dilweg, Tamara A M Mocking, Pantelis Maragkoudakis, Gerard J P van Westen, Laura H Heitman, Adriaan P IJzerman, Willem Jespers, Daan van der E. Stereochemical optimization of RSC medicinal chemistry. 2024-09-30. PMID:39345718. |
inhibition of net-mediated reuptake of norepinephrine by monoamine reuptake inhibitors has been the main therapeutic strategy to treat disorders such as depression, adhd and parkinson's disease. |
2024-09-30 |
2024-10-02 |
Not clear |
| Guilherme Fusetto Veronesi, Alessandra Gabellone, Anneka Tomlinson, Marco Solmi, Christoph U Correll, Samuele Cortes. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. Neuroscience and biobehavioral reviews. 2024-06-24. PMID:38914177. |
while several pharmacological and non-pharmacological interventions had evidence of superiority compared to the control condition from a single rct, centanafadine (norepinephrine, dopamine, and serotonin re-uptake inhibitor) was the only treatment with evidence of efficacy on adhd core symptoms (small effect size=0.28-0.40) replicated in at least one additional rct, alongside reasonable tolerability. |
2024-06-24 |
2024-06-27 |
Not clear |
| Geeta Ilipilla, L Eugene Arnol. The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. Expert opinion on pharmacotherapy. 2024-06-20. PMID:38900676. |
due to their effects on norepinephrine, dopamine, and serotonin neurotransmission, they benefit both adhd and comorbid disorders and have some other advantages including longer duration of action and fewer adverse effects compared to stimulants. |
2024-06-20 |
2024-06-23 |
Not clear |
| Fumika Sato, Akihito Suzuki, Keisuke Noto, Toshinori Shirata, Muneaki Kanno, Ryota Kobayashi, Koichi Otan. Serotonin syndrome induced by overdose of atomoxetine alone in a patient with attention-deficit hyperactivity disorder: A case report. PCN reports : psychiatry and clinical neurosciences. vol 1. issue 3. 2024-06-13. PMID:38868692. |
atomoxetine is a norepinephrine reuptake inhibitor used for the treatment of attention-deficit hyperactivity disorder (adhd). |
2024-06-13 |
2024-06-15 |
Not clear |
| Kamilla W Miskowiak, Zacharias K Obel, Riccardo Gugliemo, Caterina Del Mar Bonnin, Christopher R Bowie, Vicente Balanzá-Martínez, Katherine E Burdick, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V Kessing, Beny Lafer, Kathryn E Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S McIntyre, Richard J Porter, Scot E Purdon, Ayal Schaffer, Paul R A Stokes, Tomiki Sumiyoshi, Ivan J Torres, Tamsyn E Van Rheenen, Lakshmi N Yatham, Allan H Young, Eduard Vieta, Gregor Hasle. Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. Bipolar disorders. 2024-03-04. PMID:38433530. |
abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (bd) and attention-deficit hyperactivity disorder (adhd). |
2024-03-04 |
2024-03-06 |
Not clear |
| X Zhang, M S Berridge, S M Apana, W Slikker, M G Paule, John Talpo. Discontinuation of methylphenidate after long-term exposure in nonhuman primates. Neurotoxicology and teratology. 2023-03-09. PMID:36893929. |
the blockage of the dopamine transporter (dat) and the norepinephrine transporter (net) by mph may help with adhd symptoms by boosting monoamine levels in the synapse. |
2023-03-09 |
2023-08-14 |
human |
| Damian Koevoet, P K H Deschamps, J L Keneman. Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder. Frontiers in neuroscience. vol 16. 2023-01-23. PMID:36685234. |
deficiencies in catecholaminergic systems [dopamine (da), norepinephrine (ne)] in adhd are obvious targets for stimulant treatment. |
2023-01-23 |
2023-08-14 |
Not clear |
| Maeri Yamamoto, Toshiya Inad. Positron emission tomography studies in adult patients with attention-deficit/hyperactivity disorder. Japanese journal of radiology. 2022-12-08. PMID:36480104. |
we found that, although, disturbances of dopamine, serotonin, and norepinephrine functions have been implicated in adhd, no characteristic findings have been identified from pet studies in patients with adhd. |
2022-12-08 |
2023-08-14 |
Not clear |
| b' Jind\\xc5\\x99ich Mourek, Jaroslav Pokorn\\xc3\\xb. ADHD - What Is the Meaning of Sex-dependent Incidence Differences? Prague medical report. vol 123. issue 4. 2022-11-23. PMID:36416460.' |
the picture of adhd includes various cognitive dysfunctions with one possible cause in norepinephrine and dopamine insufficiency. |
2022-11-23 |
2023-08-14 |
Not clear |
| Sonia Carreón-Trujillo, Daniela Vázquez-González, Juan Carlos Coron. Atomoxetine Decreases Mitochondrial Biogenesis, Fission and Fusion In Human Neuron-like Cells But Does Not Alter Antioxidant Defences. Cell biochemistry and biophysics. 2022-11-08. PMID:36346546. |
atomoxetine (atx) is a presynaptic norepinephrine transporter (net) inhibitor widely prescribed for attention-deficit/hyperactivity disorder (adhd) due to its low abuse potential and absence of psychostimulant effects. |
2022-11-08 |
2023-08-14 |
human |
| Maria Ptukha, Zoia Fesenko, Anastasia Belskaya, Arina Gromova, Arseniy Pelevin, Natalia Kurzina, Raul R Gainetdinov, Anna Volnov. Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats. Biomolecules. vol 12. issue 10. 2022-10-27. PMID:36291693. |
atomoxetine (atx) is a selective norepinephrine transporter (net) inhibitor that is currently used for adhd treatment. |
2022-10-27 |
2023-08-14 |
rat |
| Anna Kabanova, Elena Cavani, Nikos K Logothetis, Oxana Eschenk. Feasibility of Canine Adenovirus Type 2 (CAV2) Based Vector for the Locus Coeruleus Optogenetic Activation in Non-Transgenic Rats: Implications for Functional Studies. Brain sciences. vol 12. issue 7. 2022-07-27. PMID:35884711. |
the locus coeruleus norepinephrine (lc-ne) system modulates many visceral and cognitive functions, while lc-ne dysfunction leads to neurological and neurodegenerative conditions such as sleep disorders, depression, adhd, or alzheimer's disease. |
2022-07-27 |
2023-08-14 |
rat |
| b' Jue Huang, Nicole Mauche, Michael Rullmann, Christine Ulke, Georg-Alexander Becker, Marianne Patt, Franziska Zientek, Swen Hesse, Osama Sabri, Maria Strau\\xc3\\x9. Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Brain sciences. vol 12. issue 8. 2022-07-27. PMID:35892406.' |
association between individual norepinephrine transporter (net) availability and response to pharmacological therapy in adults with attention-deficit/hyperactivity disorder (adhd). |
2022-07-27 |
2023-08-14 |
Not clear |
| b' Jue Huang, Nicole Mauche, Michael Rullmann, Christine Ulke, Georg-Alexander Becker, Marianne Patt, Franziska Zientek, Swen Hesse, Osama Sabri, Maria Strau\\xc3\\x9. Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Brain sciences. vol 12. issue 8. 2022-07-27. PMID:35892406.' |
the role of the norepinephrine transporter (net) has received increased focus in recent studies on the pathogenesis of attention-deficit/hyperactivity disorder (adhd). |
2022-07-27 |
2023-08-14 |
Not clear |